CRI Kasauli Launches Td Vaccine for Universal Immunisation Programme

CRI Kasauli Launches Td Vaccine for Universal Immunisation Programme

Union Health Minister J.P. Nadda launched an indigenously manufactured Tetanus and Adult Diphtheria (Td) vaccine at the Central Research Institute (CRI), Kasauli, Himachal Pradesh, on February 21, 2026. The vaccine is intended for use under India’s Universal Immunisation Programme (UIP).

Manufacturing and supply

CRI completed the vaccine’s manufacturing and testing process, including developmental studies and regulatory clearances: a Test License, waivers for preclinical and clinical trials, Marketing Authorization, and a licence for manufacture and sale. The vaccine was released by the Central Drugs Laboratory. CRI is expected to supply 55 lakh doses to the UIP by April 2026.

Replacement of the TT vaccine

The Td vaccine replaces the Tetanus Toxoid (TT) vaccine in the immunisation programme for all age groups, including pregnant women. The change follows recommendations from the National Technical Advisory Group on Immunization (NTAGI) and the World Health Organization (WHO).

Important Facts for Exams

  • Combination contents: Td combines diphtheria and tetanus toxoids; unlike Tdap, it does not include pertussis vaccine in its formulation.
  • Reduced diphtheria component: Td contains less diphtheria toxoid; its lowercase “d” denotes this reduced component compared with the capitalised “T”.
  • Toxoid mechanism: Formaldehyde detoxifies tetanus toxin while preserving most of its epitopes, enabling immune recognition without the toxin’s toxic action.
Category: Himachal Pradesh
Originally written on February 21, 2026 and last modified on November 19, 2026.
Tags: , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *